Summary: The Centers for Medicare & Medicaid Services modified its apheresis (therapeutic pheresis) coverage policy, effective May 15, 2026. Here's what billing teams need to do.
CMS updated its apheresis coverage policy governing therapeutic pheresis procedures billed to Medicare. The policy does not list specific CPT or HCPCS codes in the available data — but therapeutic pheresis billing carries real denial risk when documentation doesn't match medical necessity criteria. If your practice performs plasmapheresis, plateletpheresis, leukapheresis, or other pheresis procedures for Medicare beneficiaries, this update affects you.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Apheresis (Therapeutic Pheresis) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, nephrology, neurology, oncology, rheumatology, apheresis centers |
| Key Action | Review documentation and medical necessity criteria for all therapeutic pheresis claims before May 15, 2026 |
CMS Therapeutic Pheresis Coverage Criteria and Medical Necessity Requirements 2026
The CMS apheresis coverage policy is one of the more clinically specific policies in Medicare billing. Coverage for therapeutic pheresis is not automatic. CMS requires that each procedure meet strict medical necessity criteria — and that your documentation proves it.
Therapeutic pheresis is covered when used to treat conditions where removal of a blood component directly addresses the underlying disease process. Think myasthenia gravis, Guillain-Barré syndrome, thrombotic thrombocytopenic purpura (TTP), hyperviscosity syndromes, or certain autoimmune conditions. These aren't informal examples — they represent the kinds of diagnoses CMS has historically recognized as medically necessary indications for apheresis reimbursement.
The real issue here is specificity. "Patient needs plasmapheresis" is not sufficient documentation. Your physician's order and clinical notes must link the specific pheresis modality — plasmapheresis, leukapheresis, erythrocytapheresis, plateletpheresis — to a diagnosed condition that meets criteria. If the note doesn't make that connection explicitly, you're exposed to claim denial.
Prior authorization requirements for therapeutic pheresis vary by Medicare Administrative Contractor (MAC). Some MACs have issued local coverage determinations (LCDs) that layer additional criteria on top of the national policy. Check your MAC's current LCD for apheresis before assuming the national policy is your only reference point. This is a critical step many billing teams skip — and it's where denials accumulate.
The effective date of May 15, 2026 means any claims for services rendered on or after that date must conform to the updated criteria. Pull the full policy from the CMS source now, not after your first denial.
CMS Apheresis Exclusions and Non-Covered Indications
Not every use of a pheresis machine is a covered service under Medicare. CMS draws a firm line between therapeutic pheresis — where the procedure treats the condition — and collection procedures used for donor purposes or other non-therapeutic applications.
Apheresis performed solely to collect components for transfusion to another patient is not covered under the therapeutic pheresis coverage policy. Similarly, procedures performed for conditions that CMS considers to lack sufficient clinical evidence — where the use of therapeutic pheresis is deemed investigational — will not be reimbursed under this policy.
The harder category is "off-label" or emerging uses. Some conditions appear in medical literature as potential apheresis candidates but haven't cleared CMS's medical necessity bar. If your physicians are ordering pheresis for a diagnosis that isn't on the established covered indications list, that claim will almost certainly be denied. Talk to your compliance officer before billing those cases.
Cosmetic or elective procedures involving apheresis equipment are also not covered. That should go without saying, but it comes up in audits more than you'd expect.
Coverage Indications at a Glance
The available policy data does not include a detailed indication-by-indication coverage table. The table below reflects well-established CMS coverage positions for therapeutic pheresis based on the policy category. Verify the current criteria against the full CMS policy document and your MAC's LCD before billing.
| Indication | Status | Notes |
|---|---|---|
| Thrombotic thrombocytopenic purpura (TTP) | Covered | Strong medical necessity basis; document acute presentation |
| Myasthenia gravis (refractory) | Covered | Must document failure of standard treatment |
| Guillain-Barré syndrome | Covered | Document neurological severity and treatment rationale |
| Hyperviscosity syndromes (e.g., Waldenström's) | Covered | Link diagnosis to specific pheresis modality in documentation |
| Sickle cell disease (erythrocytapheresis) | Covered | Stroke prevention and acute chest syndrome; MAC criteria may apply |
| Familial hypercholesterolemia (LDL apheresis) | Covered (with criteria) | Specific criteria apply; prior authorization may be required by MAC |
| Donor/collection apheresis | Not Covered | Not therapeutic in nature; billed under different pathways |
| Investigational/emerging indications | Not Covered | Lack sufficient clinical evidence per CMS standards |
| Cosmetic or elective apheresis applications | Not Covered | No clinical necessity basis |
This table is a reference starting point. The policy does not list specific CPT or HCPCS codes in the available data, and CMS's full policy document may contain more granular indication criteria. Treat this as a map, not a substitute for the source document.
CMS Therapeutic Pheresis Billing Guidelines and Action Items 2026
The modified policy takes effect May 15, 2026. Here's what your billing team needs to do before that date.
| # | Action Item |
|---|---|
| 1 | Pull the full CMS policy and your MAC's LCD now. The national policy sets the floor. Your Medicare Administrative Contractor may have issued an LCD that adds criteria, restricts coverage, or specifies documentation requirements beyond what CMS publishes. Search the Medicare Coverage Database and your MAC's website using "apheresis" and "therapeutic pheresis." Do this before May 15, 2026. |
| 2 | Audit your current therapeutic pheresis claims for documentation gaps. Run a 90-day lookback on all therapeutic pheresis claims. Check that each has a physician order, a diagnosis that maps to a covered indication, documentation of medical necessity, and clinical notes that support the specific modality used. If any of those elements are missing, you have a pattern problem to fix now. |
| 3 | Confirm prior authorization status with each patient's MAC before scheduling. Prior authorization requirements for therapeutic pheresis are MAC-specific. Some contractors require it; others don't. Calling this out with your scheduling team prevents the worst-case scenario: a completed procedure with no authorization and no reimbursement. |
| 4 | Update your charge capture templates to include indication-specific documentation prompts. If your EHR or charge capture system doesn't prompt for the covered diagnosis, the modality, and the medical necessity rationale, update it before the effective date. A prompt during charge entry costs nothing. A denied claim costs time, money, and sometimes the whole reimbursement. |
| 5 | Train your coding staff on the difference between therapeutic and non-therapeutic apheresis. This is where billing guidelines get blurry in practice. Donor collection procedures, stem cell mobilization apheresis, and therapeutic apheresis all involve the same equipment but bill differently and have different coverage rules. Your coders need to know which is which without guessing. |
| 6 | Flag complex or off-label cases for compliance review before billing. If a physician is ordering therapeutic pheresis for a diagnosis that isn't clearly on the covered indications list, don't just bill it and wait for the denial. Loop in your compliance officer before the claim goes out. The cost of a pre-submission review is far lower than a recoupment audit. |
| 7 | Set a calendar reminder for the May 15, 2026 effective date. Claims for services on or after that date fall under the updated policy. Claims before that date fall under the prior version. Keep that line clear in your billing system. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Therapeutic Pheresis Under CMS Policy
The CMS apheresis coverage policy data provided does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. Do not assume any code is covered or not covered based on this post alone.
Therapeutic pheresis billing typically involves HCPCS codes for the procedure itself, but CMS has not published a code list in the available policy data. Your MAC's LCD is the most reliable source for the exact codes covered under this policy.
What to do instead:
Search the Medicare Coverage Database at cms.gov for "therapeutic pheresis" to find associated NCDs, LCDs, and billing articles that specify accepted codes. Cross-reference with your MAC's billing article for apheresis, which will list the exact HCPCS codes and any required modifiers.
If you're not sure which codes your MAC accepts for the specific pheresis modality your facility performs — plasmapheresis, erythrocytapheresis, leukapheresis, LDL apheresis — call your MAC's provider relations line directly. This is not a situation where guessing serves you well.
Do not fabricate or assume codes based on general knowledge. The wrong code on a therapeutic pheresis claim doesn't just get denied — it can trigger a medical review flag. Get the right codes from the right source before the May 15, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.